U.S. FDA Approves AbbVie's JUVMO™ (tavapadon) for Parkinson's Disease
RegulatoryapprovedJUVMOPositive
AI Analysis
Summary
The U.S. FDA has approved AbbVie's JUVMO (tavapadon), the first and only selective D1/D5 receptor agonist for treating adults with Parkinson's disease. JUVMO is administered once daily and can be used with or without levodopa therapy.
Outcome Details
FDA approval for JUVMO (tavapadon) as first and only selective D1/D5 receptor agonist for Parkinson's disease
Importance:9/10
Sentiment:
0.95
FDA approvalParkinson's diseasefirst-in-classneurology
Related Companies
Read the original article
Published by PR Newswire Biotech on September 28, 2026 12:00 PM